Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: A phase 2 clinical trial

JAMA Oncology

Volumn 4, Issue 2, 2018, Pages 230-234

  Jabbour, Elias ^a   Ravandi, Farhad ^a   Kebriaei, Partow ^a   Huang, Xuelin ^a   Short, Nicholas J ^a   Thomas, Deborah ^a   Sasaki, Koji ^a   Rytting, Michael ^a   Jain, Nitin ^a   Konopleva, Marina ^a   Garcia Manero, Guillermo ^a   Champlin, Richard ^a   Marin, David ^a   Kadia, Tapan ^a   Cortes, Jorge ^a   Estrov, Zeev ^a   Takahashi, Koichi ^a   Patel, Yogin ^a   Khouri, Maria R ^a   Jacob, Jovitta ^a   Garris, Rebecca ^a   O'Brien, Susan ^b   Kantarjian, Hagop ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; INOTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; PEGFILGRASTIM; PREDNISONE; RITUXIMAB; URSODEOXYCHOLIC ACID; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGE DISTRIBUTION; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; RECURRENCE FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL TIME; TEXAS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VEIN OCCLUSION; ADOLESCENT; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PHILADELPHIA 1 CHROMOSOME; PROCEDURES; RECURRENT DISEASE; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; SURVIVAL ANALYSIS; VINCRISTINE; YOUNG ADULT;

EID: 85045950102     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.2380     Document Type: Article

References (11)

1. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010;116(24):5568-5574.
2. Tavernier E, Boiron JM, Huguet F, et al; GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007;21(9):1907-1914.
3. Gökbuget N, Stanze D, Beck J, et al; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012;120(10):2032-2041.
4. Frey NV, Luger SM. How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Blood. 2015;126(5):589-596.
5. Kantarjian HM, DeAngelo DJ, StelljesM, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740-753.
6. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24): 3880-3889.
7. Ravandi F, Jorgensen JL, O'Brien SM, et al. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2016;172 (3):392-400.
8. Austin PC, Stuart EA.Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661-3679.
9. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9):836-847.
10. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411.
11. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013;119(15): 2728-2736.